[HTML][HTML] Biomedical polymers: synthesis, properties, and applications

WH Chen, QW Chen, Q Chen, C Cui, S Duan… - Science China …, 2022 - Springer
Biomedical polymers have been extensively developed for promising applications in a lot of
biomedical fields, such as therapeutic medicine delivery, disease detection and diagnosis …

Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual …

SJ Head, M Milojevic, J Daemen, JM Ahn, E Boersma… - The Lancet, 2018 - thelancet.com
Background Numerous randomised trials have compared coronary artery bypass grafting
(CABG) with percutaneous coronary intervention (PCI) for patients with coronary artery …

Wearable and implantable devices for cardiovascular healthcare: from monitoring to therapy based on flexible and stretchable electronics

YJ Hong, H Jeong, KW Cho, N Lu… - Advanced Functional …, 2019 - Wiley Online Library
Cardiovascular disease is the leading cause of death and has dramatically increased in
recent years. Continuous cardiac monitoring is particularly important for early diagnosis and …

Coronary In-Stent Restenosis: JACC State-of-the-Art Review

G Giustino, A Colombo, A Camaj, K Yasumura… - Journal of the American …, 2022 - jacc.org
The introduction and subsequent iterations of drug-eluting stent technologies have
substantially improved the efficacy and safety of percutaneous coronary interventions …

[HTML][HTML] Drug-eluting or bare-metal stents for coronary artery disease

KH Bønaa, J Mannsverk, R Wiseth… - … England Journal of …, 2016 - Mass Medical Soc
Background Limited data are available on the long-term effects of contemporary drug-eluting
stents versus contemporary bare-metal stents on rates of death, myocardial infarction, repeat …

[HTML][HTML] A tough nitric oxide-eluting hydrogel coating suppresses neointimal hyperplasia on vascular stent

Y Chen, P Gao, L Huang, X Tan, N Zhou, T Yang… - Nature …, 2021 - nature.com
Vascular stent is viewed as one of the greatest advancements in interventional cardiology.
However, current approved stents suffer from in-stent restenosis associated with neointimal …

Wearable and implantable devices for drug delivery: Applications and challenges

A Kar, N Ahamad, M Dewani, L Awasthi, R Patil… - Biomaterials, 2022 - Elsevier
Poor adherence to drug dosing schedule is responsible for∼ 50% of hospitalization cases.
Most patients fail to adhere to a strict dosing schedule due to invasive drug administration …

[PDF][PDF] 2014 ESC/EACTS Guidelines on myocardial revascularization

S Windecker, P Kolh, F Alfonso… - Kardiologia Polska …, 2014 - journals.viamedica.pl
Zachęca się pracowników opieki zdrowotnej, aby w pełni uwzględniali te wytyczne
ESC/EACTS, gdy dokonują oceny klinicznej, a także kiedy określają i realizują medyczne …

[HTML][HTML] Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment

D Buccheri, D Piraino, G Andolina… - Journal of thoracic …, 2016 - ncbi.nlm.nih.gov
The lumen diameter reduction after percutaneous coronary intervention (PCI) is well known
as “restenosis”. This phenomenon is due to vessel remodeling/recoil in case of no-stent …

Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

J Escaned, C Collet, N Ryan… - European heart …, 2017 - academic.oup.com
Aims To investigate if recent technical and procedural developments in percutaneous
coronary intervention (PCI) significantly influence outcomes in appropriately selected …